Clinical Trial

A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma

Study acronym: MRG003-SACC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This prospective, multicenter clinical study aims to evaluate the efficacy and safety of neoadjuvant therapy with MRG003 (Becotatug vedotin) combined with epirubicin in patients with EGFR-positive, unresectable recurrent sinonasal adenoid cystic carcinoma (SNACC). The primary question is whether this combination can achieve a sufficient objective response rate (ORR) to enable subsequent radical surgery or improve disease control.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-13
Trial Details
NCT Number NCT07522879
Lead Sponsor Eye & ENT Hospital of Fudan University
Conditions Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Enrollment 40 participants
Start Date 2026-04-28
Primary Completion 2028-10-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-28